Characterization of an in vitro platelet function analyzer, PFA-100™

Clinical and Applied Thrombosis/Hemostasis

Volumn 2, Issue 4, 1996, Pages 241-249

  Kundu, Sourav K ^a   Heilmann, Eric J ^a   Sio, Reynaldo ^a   Garcia, Carmen ^a   Ostgaard, Roy A ^a  

^a Dade International Inc   (United States)

Author keywords

Analyzer; Blood; In vitro; Platelet function; Test

Indexed keywords

EID: 0000297376     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969600200404     Document Type: Article

References (34)

1. George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991;324: 27-39.
2. Dick RL. Platelet function defects associated with hemorrhage or thrombosis. Med Clin North Am 1994;78:577-607.
3. Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1-20.
4. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991;77:2547-52.
5. Kratzer MAA, Born GVR. Simulation of primary haemostasis in vitro. Haemostasis 1985;15:357-62.
6. Kratzer MAA, Bellucci S, Caen JP. Detection of abnormal platelet functions with an in vitro model of primary haemostasis. Haemostasis 1985;15:363-70.
7. Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100™ system. Semin Thromb Hemost 1995;21(suppl.2):113-21.
8. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer-PPA-100™. Semin Thromb Hemost 1995;21(suppl 2):106-12.
9. Pietu G, Fressinaud E, Girma J, Nieuwenhuis H, Rothschild C, Meyer D. Binding of human von Willebrand factor to collagen and to collagen-stimulated platelets. J Lab Clin Med 1987;109:637-46.
10. Takahashi Y, Kalafatis M, Girma J, Sewerin K, Andersson L, Meyer D. Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor. Blood 1987;70:1679-82.
11. Dietrich G, Kretschmer V, Orth D, Haupt W. Primary hemostasis in hemodilution - 1) Hematocrit. Infusionstherapie 1990;17:212-3.
12. Ruggeri ZM. Mechanism of shear-induced platelet adhesion and aggregation. Thromb Haemost 1993;70:119-23.
13. Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffman T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 1989;83:288-97.
14. Hantgan RR, Hindricks G, Taylor RG, Sixma JJ, de Groot PG. Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb:IIIa are all involved in platelet adhesion to fibrin in flowing blood. Blood 1990;76:345-53.
15. Ikeda Y, Handa M, Kawano K, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991;87:1234-40.
16. Alevriadou BR, Moake JL, Turner NA, et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993;81:1263-76.
17. 1746 sequence in the GPIIb-IIIa-binding domain of von Willebrand factor is involved in platelet adhesion and thrombus formation on subendothelium. J Lab Clin Med 1993;122:324-32.
18. Lam S, Smith M, Plow E, et al. Evidence that arginyl-glycyl-aspartate peptides and fibrinogen gamma chain peptides share a common binding site on platelets. J Biol Chem 1987; 262:947-50.
19. Kundu S, Sio R, Mitu A, Ostgaard R. Evaluation of platelet function by PFA-100™. Clin Chem 1994;40:1827-8.
20. Kehrel B, Kronenberg A, Rauterberg J, et al. Platelets deficient in glycoprotein IIIb aggregate normally to collagens type I and III but not to collagen type V. Blood 1993;82: 3364-70.
21. 1-integrin). Blood 1994;83:1244-50.
22. 1-recognition sites in colla-gen type I. Biochem J 1994;299:791-7.
23. McKeown L, Vail M, Williams S, Kramer W, Hansmann K, Gralnick H. Platelet adhesion to collagen in individuals lacking glycoprotein IV. Blood 1994;83:2866-71.
24. Hellem AJ, Borchrevink CF, Ames SB. The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesiveness. Br J Haematol 1961;7:42-50.
25. Livio M, Gotti E, Marchesi D, Remuzzi G, Mecca G, de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusion. Lancet 1982;ii:1013-5.
26. Turitto VT, Weiss HJ. Rheological factors influencing platelet interaction with vessel surfaces. J Rheology 1979;23:35-49.
27. Aarts PAMM, Heethaar RM, Sixma JJ. Red blood cell deformability influences platelet-vessel wall interaction in flowing blood. Blood 1984;64:1228-33.
28. Boneu B, Fernandez F. The role of the hematocrit in bleeding. Transfus Med Rev 1987;1:182-5.
29. Blajchman MA, Bordin JO, Bardossy L, Heddle NM. The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. Br J Haematol 1994;86:347-50.
30. Alshameeri RS, Mammen EF. Clinical experience with the Thrombostat 4000. Semin Thromb Hemost 1995;21(suppl. 2):1-10.
31. Kretschmer V, Schikor B, Söhngen D, Dietrich G. In vitro bleeding test - a simple method for the detection of aspirin effects on platelet function. Thromb Res 1989;56:593-602.
32. Tsujinaka T, Itoh T, Ufmura Y, Sakon M, Kambayashi J, Mori T. Clinical application of a new in vitro bleeding time device on surgical patients. Jpn J Surg 1988;18:430-7.
33. Kristensen J, Eriksson L, Olsson K, Killander A, Högman C. Functional capacity of transfused platelets estimated by the Thrombostat 4000/2. Eur J Haematol 1993;51:152-5.
34. Kretschmer V, Huss B, Dietrich G, Heymanns J, Pflüger K. Determination of bleeding risk in thrombocytopenic patients receiving platelet substitution. Transfus Sci 1993;14 27-34.